Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,537JPY
17 Aug 2018
Change (% chg)

¥-76 (-1.65%)
Prev Close
¥4,613
Open
¥4,600
Day's High
¥4,607
Day's Low
¥4,537
Volume
4,005,800
Avg. Vol
5,186,332
52-wk High
¥6,693
52-wk Low
¥4,203

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥4,891,410.00
Shares Outstanding(Mil.): 790.85
Dividend: 90.00
Yield (%): 2.91

Financials

  4502.T Industry Sector
P/E (TTM): 30.36 30.93 32.76
EPS (TTM): 203.74 -- --
ROI: 5.07 15.07 14.61
ROE: 8.38 16.59 16.33

UPDATE 2-Takeda operating profit halves, looks to asset sales to shore up finances

* Shire-related costs helped push debt ratio higher (Adds details from news conference)

31 Jul 2018

Takeda Q1 profit tumbles 49 pct after asset sales, hit by generic drug competition

TOKYO, July 31 Japan's Takeda Pharmaceutical Co Ltd on Tuesday reported a 49 percent fall in first-quarter operating profit, affected by asset sales booked in the same quarter a year earlier and by generic drug competition for blood cancer treatment Velcade in the U.S.

31 Jul 2018

Buy yen in crisis? Not this year

LONDON/TOKYO The trade is familiar to investors worldwide: in times of turmoil, rush for cover by buying the Japanese yen.

24 Jul 2018

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

10 Jul 2018

UPDATE 2-Japan's Takeda gains US approval for $62 bln Shire buy

* Also needs approval from Takeda, Shire shareholders (Adds share movement)

10 Jul 2018

Takeda gets key U.S. regulatory approval to buy Shire

TOKYO, July 10 Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc .

10 Jul 2018

Japan's Takeda to sell Osaka headquarters, could raise 60 billion yen: Nikkei

TOKYO Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc , the Nikkei business daily reported on Thursday.

05 Jul 2018

Japan's Takeda to sell Osaka headquarters, could raise Y60 bln - Nikkei

TOKYO, July 5 Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc, the Nikkei business daily reported on Thursday.

05 Jul 2018

Q2 slowdown hits Asian lending

Hong Kong, June 29 (TRLPC) - Syndicated lending in Asia Pacific, excluding Japan, showed a steep 31% year-on-year decline to US$94.17bn in the second quarter, dragging first-half borrowing volumes down 9.2% to US$211.60bn, according to Thomson Reuters LPC data.

29 Jun 2018

Return of mega-deals helps European M&A double

LONDON A resurgence in mega-deals has led to a doubling of mergers and acquisitions activity in Europe so far this year, raising questions among bankers and lawyers about when the pace of blockbuster transactions will start to fade.

29 Jun 2018

Earnings vs. Estimates